Potentiation of the Cytotoxic Effects of Imatinib and TRAIL by Nonsteroidal Anti-inflammatory Drugs on Human Cancer Cells

국문 초록 (Abstract)

항암 요법의 실패의 주요 원인으로 암세포의 항암제에 대한 내성 획득이 잘 알려져 있다. 비스테로이드소염제(NSAID)는 항염증작용뿐만 아니라 항암제와의 병용요법으로 임상적인 암 치료 요법에 응용되고있다. 본 연구에서는 NSAIDs 인 celecoxib 및 이의 구조 유사체인 2,5-dimethyl celecoxib 그리고 ibuprofen의 인간 암세포에 대한 imatinib 및 TNF-related apoptosis inducing ligand (TRAIL) 세포 독성 변화에 미치는 영향을 조사하였다. NSAID는 TRAIL 및 imatinib에 각각 약제 내성을 나타내는 간암 세포와 백혈병 세포에서 이들 약물의 세포독성을 증강시키는 활성을 나타내었다. NSAID는 ATF4/CHOP의 발현 증강으로 소포체 스트레스 및 오토파지(Autophagy, 자가포식)를 유도하였다. 이로 인한 DR5 발현 증강과 함께 c-FLIP 발현 억제로 TRAIL의 세포독성을 증강시키는 기전을 나타내었다. NSAID로 유도되는 오토파지 활성은 imatinib-resistant CD44<SUP>high</SUP>K562 백혈병세포의 imatinib 감수성을 증강시켰으며, NSAID는 이 세포에서 높은 발현을 나타내는 다양한 stemness-related marker 단백질의 발현 감소를 촉진시키는 활성으로 세포사멸을 유도하는 것을 알 수 있었다. 이러한 결과는 NSAID의 오토파지 유도 활성이 TRAIL과 imatinib의 세포 독성을 증강시키는 것으로서, NSAID와 이들 약물과 병용 처리 방법은 인간 암세포의 TRAIL 및 imatinib 내성을 극복 시킴과 동시에 암세포에 이들 약물의 독성 부작용을 감소시킬 수 있는 낮은 농도의 처리를 가능하게 할 것으로 사료된다.

다국어 초록 (Multilingual Abstract)

The resistance of cancer cells to anti-cancer drugs is the leading cause of chemotherapy failure. The clinical use of nonsteroidal anti-inflammatory drugs (NSAIDs) has been gradually extended to cancer treatment through combination with anti-cancer drugs. In the current study, we investigated whether NSAIDs including celecoxib (CCB), 2,5-dimethyl celecoxib (DMC), and ibuprofen (IBU) could enhance the cytotoxic effects of imatinib and TNF-related apoptosis inducing ligand (TRAIL) on human cancer cells. We found that the NSAIDs potentiated TRAIL and imatinib cytotoxicity against human hepatocellular carcinoma (HCC) cell lines SNU-354, SNU-423, SNU-449, and SNU-475/TR and against leukemic K562 cells with high level of CD44 (CD44<SUP>high</SUP>K562), respectively. More specifically, CCB induced endoplasmic reticulum stress via up-regulation of ATF4/CHOP which is associated with the induction of autophagy against HCC and CD44<SUP>high</SUP> K562 cells. NSAID-induced autophagic activity accelerated TRAIL cytotoxicity of HCC cells through up- and down-regulation of DR5 and c-FLIP, respectively. The NSAIDs also potentiated imatinib-induced cytotoxicity and apoptosis through down-regulation of markers in CD44<SUP>high</SUP>K562 cells that express a stemness phenotype. Our results suggest that the ability of NSAIDs to induce autophagy could enhance the cytotoxicity of TRAIL and imatinib, leading to a reverse resistance to these drugs in the cancer cells. In conclusion, NSAIDs in combination with low-dose TRAIL or imatinib may constitute a novel clinical strategy that maximizes therapeutic efficacy of each drug and effectively reduces the toxic side effects.

목차 (Table of Contents)

• Introduction
• Materials and Methods
• Results
• Discussion
• References
• 초록

참고문헌 (Reference)

1 Gomez-Sanchez, R., "mRNA and protein dataset of autophagy markers(LC3 and p62)in several cell lines" 7 : 641-647, 2016

2 Zhan, T., "Wnt signaling in cancer" 36 : 1461-1473, 2017

3 Mills, K. R., "Tumor necrosis factor-related apoptosis-inducing ligand(TRAIL)is required for induction of autophagy during lumen formation in vitro" 101 : 3438-3443, 2004

4 Thomas, X., "The development of agents targeting the BCR-ABL tyrosine kinase as Philadelphia chromosome-positive acute lymphoblastic leukemia treatment" 11 : 1061-1070, 2016

5 Hu, H., "The C/EBP homologous protein(CHOP)transcription factor functions in endoplasmic reticulum stress-induced apoptosis and microbial infection" 9 : 3083-, 2018

6 Taylor, M. A., "Targeting autophagy for combating chemoresistance and radioresistance in glioblastoma" 23 : 563-575, 2018

7 Chen, S., "Targeted therapy for hepatocellular carcinoma : Challenges and opportunities" 460 : 1-9, 2019

8 Lu, G., "Synergistic effect of celecoxib on TRAIL-induced apoptosis in hepatocellular carcinoma cells" 28 : 629-634, 2010

9 Kim, H. B., "Sensitization of chemo-resistant human chronic myeloid leukemia stem-like cells to Hsp90 inhibitor by SIRT1 inhibition" 11 : 923-934, 2015

10 Yu, Y., "Psoralen induces hepatic toxicity through PERK and ATF6 related ER stress pathways in HepG2 cells" 30 : 39-47, 2020

11 Liu, Z., "Protein kinase R-like ER kinase and its role in endoplasmic reticulum stress-decided cell fate" 6 : e1822-, 2015

12 Lee, S. H., "Potential role of CD133 expression in the susceptibility of human liver cancer stem-like cells to TRAIL" 24 : 495-509, 2016

13 Schror, K., "Pharmacology and cellular/molecular mechanisms of action of aspirin and non-aspirin NSAIDs in colorectal cancer" 25 : 473-484, 2011

14 Nazim, U. M., "Ophiopogonin B sensitizes TRAIL-induced apoptosis through activation of autophagy flux anddownregulates cellular FLICE-like inhibitory protein" 9 : 4161-4172, 2018

15 Yoon, M. J., "Monensin, a polyether ionophore antibiotic, overcomes TRAIL resistance in glioma cells via endoplasmic reticulum stress, DR5upregulation and c-FLIP downregulation" 34 : 1918-1928, 2013

16 Akrami, H., "Inhibitory effect of ibuprofen on tumor survival and angiogenesis in gastric cancer cell" 36 : 3237-3243, 2015

17 Thakkar, A., "Evaluation of ibuprofen loaded solid lipid nanoparticles and its combination regimens for pancreatic cancer chemoprevention" 46 : 1827-1834, 2015

18 Peng, J., "Effect of ibuprofen on autophagy of astrocytes during pentylenetetrazol-induced epilepsy and its significance : an experimental study" 44 : 2566-2576, 2019

19 Martin-Perez, R., "ER stress sensitizes cells to TRAIL through down-regulation of FLIP and Mcl-1 and PERK-dependent up-regulation of TRAIL-R2" 17 : 349-363, 2012

20 Li, X., "Combined inhibition of autophagy and Nrf2 signaling augments bortezomib-induced apoptosis by increasing ROS production and ER stress in pancreatic cancer cells" 14 : 1291-1305, 2018

21 Tsutsumi, S., "Celecoxib upregulates endoplasmic reticulum chaperones that inhibit celecoxib-induced apoptosis in human gastric cells" 25 : 1018-1029, 2006

22 Toloczko-Iwaniuk, N., "Celecoxib in cancer therapy and prevention-review" 20 : 302-315, 2019

23 Wang, K., "Autophagy and apoptosis in liver injury" 14 : 1631-1642, 2015

24 Yu, C., "Autophagy : novel applications of nonsteroidal anti-inflammatory drugs for primary cancer" 7 : 471-484, 2018

25 Yazdani, H. O., "Autophagy : dual response in the development of hepatocellular carcinoma" 8 : 91-, 2019

26 Walker, C., "Are all oral COX-2 selective inhibitors the same? A consideration of celecoxib, etoricoxib, and diclofenac" 2018 : 1302835-, 2018

27 Sobolewski, C., "2, 5-Dimethyl-celecoxib inhibits cell cycle progression and induces apoptosis in human leukemia cells" 355 : 308-328, 2015